Sterling Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$13.3K Buy
4,888
+2,919
+148% +$9.7K ﹤0.01% 2383
2026
Q2
$7.38K Buy
+1,969
New +$7.52K ﹤0.01% 2393
2018
Q3
– Sell
-37,751
Closed -$863K – 868
2018
Q2
$863K Sell
37,751
-45
-0.1% -$1.15K 0.01% 664
2018
Q1
$1.08M Hold
37,796
– – 0.01% 587
2017
Q4
$798K Buy
+37,796
New +$784K 0.01% 697

Other funds holding CTMX

Sterling Capital Management's CTMX Position: Q3 2026 in Review

Sterling Capital Management increased its CytomX Therapeutics (CTMX) stake by 148% in Q3 2026, buying an estimated $9.7K and bringing the position to 4,888 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2383.

Sterling Capital Management first reported a position in CTMX in Q4 2017 and has held it in 5 quarters since. The position peaked at $1.08M in Q1 2018. 194 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.

  • Sterling Capital Management held 4,888 shares of CytomX Therapeutics worth $13.3K as of Q3 2026.
  • Sterling Capital Management bought 2,919 CytomX Therapeutics shares in Q3 2026, an estimated $9.7K.
  • CytomX Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2383 holding.
  • Sterling Capital Management first reported a position in CytomX Therapeutics in Q4 2017 and has held it in 5 quarters since.
  • Sterling Capital Management's CytomX Therapeutics position peaked at $1.08M in Q1 2018.
  • 194 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.